Orgenesis Inc.
Unlocking the Potential of Cell and Gene Therapy for All (NASDAQ: ORGS)
Germantown, United States
65 employees
Grant
Total: $69.12M
Biotechnology, Health Care +1
General Information
Get notified when Orgenesis Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Orgenesis Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
United States Market
Biotechnology
About Orgenesis Inc.
Taxonomy: biotech, cell therapy, gene therapy, POCare Network, decentralized production, diabetes treatment, Autologous Insulin Producing (AIP) cell transplantation, beta cell replacement, pancreas islet transplantation, clinical trials, FDA guidelines, molecular and cellular approach, global biotech company, organ regeneration, insulin-dependent diabetes mellitus
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | €1.50M | 1 | Wallonia Regional Government | 13 Mar 2024 |
| Post-IPO Equity | $2.30M | - | 04 Mar 2024 | |
| Venture Round | $1.00M | - | 08 Sep 2023 | |
| Post-IPO Equity | $35.00M | 1 | Metalmark Capital | 07 Nov 2022 |
| Post-IPO Equity | Unknown | 1 |
|
28 Sep 2021 |
Orgenesis Inc. Alternatives & Competitors
Personalizing Insulin Delivery for People with Diabetes
Beta-O2 is developing the ßAir Bio-artificial Pancreas, intended to cure Type 1 diabetes (TID).
Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes
FAQ About Orgenesis Inc.
Don't just browse. Track.
Signal Tracker monitors Orgenesis Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.